Last reviewed · How we verify
ANA598
ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus.
ANA598 is a non-nucleoside inhibitor of the NS5B polymerase of the hepatitis C virus. Used for Chronic hepatitis C.
At a glance
| Generic name | ANA598 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | NS5B polymerase inhibitor |
| Target | NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 2 |
Mechanism of action
ANA598 works by binding to the NS5B polymerase, which is essential for the replication of the hepatitis C virus. This binding prevents the virus from replicating, thereby reducing the viral load in the body.
Approved indications
- Chronic hepatitis C
Common side effects
- Fatigue
- Headache
- Nausea
Key clinical trials
- Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection (PHASE2)
- A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C (PHASE2)
- A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls (PHASE1)
- A Relative Bioavailability Study of Setrobuvir Tablet Formulation Versus Reference Setrobuvir Capsule Formulation in Healthy Volunteers (PHASE1)
- Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ANA598 CI brief — competitive landscape report
- ANA598 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI